Pritchard et al. found an increased frequency of PALB2 mutations in the series of 692 men with metastatic prostate cancer when compared with a large population of people unaffected with cancer (RR 3.5, 95% CI: 0.7–10.3, p = 0.05)56. Here, PALB2 is linked to cancer.